Handelsavisen
prelaunch
Companies Healthcare M3VGN.DE
M3
M3VGN.DE XETRA Advanced Medical Equipment & Technology

Mevis Medical Solutions AG

Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
4,09 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Mevis Medical Solutions AG develops and sells software and hardware solutions for medical imaging and diagnostics, primarily serving the healthcare industry.

Business. Mevis Medical Solutions AG (M3VGN.DE) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Germany and is listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning M3VGN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to M3VGN.DE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Mevis Medical Solutions AG (M3VGN.DE) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Germany and is listed on the Xetra exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    Mevis Medical Solutions AG has a basic and diluted share count of 1,820,000 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

    The company reported a last actual EPS of 3.94 EUR and revenue of 16,758,000 EUR, suggesting a relatively strong profitability position. While no direct comparison to industry medians is available, the EPS and revenue figures indicate a solid performance for a firm in the Advanced Medical Equipment & Technology industry.

    Mevis Medical Solutions AG operates in a single business segment focused on medical imaging and diagnostics. The company's geographic exposure is not disclosed in the available data, but its primary market is likely concentrated in Europe, given its listing on the German stock exchange.

    The company's growth trajectory is not explicitly outlined in the available data, but the reported revenue and EPS figures suggest a stable or growing business. No specific growth rates or future projections are provided in the input data.

    The risk assessment indicates a low dilution risk, but the liquidity risk could not be evaluated due to missing balance-sheet data. No dilution sources are explicitly identified in the input data, and no recent events such as filings or transcripts are provided to assess potential dilution pressures.

    No recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic or operational developments. The absence of such information limits the ability to assess recent changes in the company's business model or risk profile.

    Key takeaways
    • Mevis Medical Solutions AG operates in the Advanced Medical Equipment & Technology industry with a strong focus on medical imaging and diagnostics.
    • The company has a basic and diluted share count of 1,820,000, indicating no immediate dilution pressure.
    • The last actual EPS of 3.94 EUR and revenue of 16,758,000 EUR suggest a solid profitability position.
    • The liquidity risk remains unassessed due to missing balance-sheet data and no going-concern language in the source documents.
    • The company's geographic exposure is not disclosed, but its listing on the German stock exchange suggests a European market focus.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2019-01-29
    FY 2019 · Full-year highlights

    Revenue €16.1M, −5,4% YoY; Operating income −39,0% YoY.

    Revenue€16.1M−5,4 % YoY
    Operating income€2.1M−39,0 % YoY
    Net income€3.2M−30,6 % YoY
    Free cash flow-€1.4M−163,0 % YoY
    EPS
    Operating cash flow€3.9M+23,3 % YoY
    Financials
    Income statement
    Revenue€16.1M
    Gross profit€15.7M
    Operating income€2.1M
    Net income€3.2M
    Margins
    Gross margin97.7%
    Operating margin13.3%
    Net margin19.7%
    FCF margin-8.6%
    Balance sheet
    Total assets€25.9M
    Total liabilities€8.1M
    Total equity€17.8M
    Cash & equivalents
    Long-term debt€0.00
    Cash flow
    Operating cash flow€3.9M
    CapEx-€140.4k
    Free cash flow-€1.4M
    SBC
    P&L flow · revenue → net income
    Revenue €16.1MOperating costs €13.9MNet income €3.2M
    Highlights
    • Revenue €16.1M, −5,4% YoY
    • Operating income −39,0% YoY
    • Net income −30,6% YoY
    • Free cash flow −163,0% YoY
    • Net margin 19.7%

    Valuation FY

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Mevis Medical Solutions AG Market data — financials · 2026-05-28
    • Mevis Medical Solutions AG Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Kimberley E. HoneysettChairman of the Supervisory Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    M3VGN.DECanonical
    XETRA · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2019-08-30 00:54 UTCEARNINGSQuarterly results — Q2 2019
    2019-05-23 15:00 UTCEARNINGSQuarterly results — Q1 2019
    2019-02-26 18:13 UTCEARNINGSQuarterly results — Q4 2018
    2019-01-29 17:40 UTCEARNINGSQuarterly results — Q4 2018
    2019-01-29 17:40 UTCEARNINGSAnnual results — FY 2019 Revenue EUR 16.1M · Net EUR 3.2M
    2018-08-21 07:00 UTCEARNINGSQuarterly results — Q2 2018
    2018-05-16 13:34 UTCEARNINGSQuarterly results — Q1 2018
    2018-02-20 15:00 UTCEARNINGSQuarterly results — Q4 2017
    2018-01-23 14:24 UTCEARNINGSQuarterly results — Q4 2017
    2018-01-23 14:24 UTCEARNINGSAnnual results — FY 2018 Revenue EUR 17.0M · Net EUR 4.6M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage